Quarterly Earnings

NRG Energy names insider Robert J. Gaudette as its next CEO, signaling strategic continuity as the energy giant navigates a market in transformation.

As Sotera Health prepares for the J.P. Morgan conference, strong financials clash with legal challenges, putting its mission-critical role under scrutiny.

Apogee Enterprises taps a veteran insider as interim CFO after Matthew Osberg's exit coincides with a sharp stock drop and reduced financial guidance.

Following record financial growth, RadNet promotes four executives to accelerate its shift toward proactive, AI-driven healthcare and expand its market dominance.

As Radware preps its 2025 results, investors watch to see if its AI-driven strategy can sustain growth and outpace rivals in a booming cybersecurity market.

Alerus Financial is set to release its Q4 results, capping a year of strategic growth. Investors watch to see if its unique model can sustain momentum.

As COO/CFO Ashim Gupta prepares for a key investor conference, UiPath aims to prove its 'agentic automation' strategy can deliver sustained growth.

LifeVantage heads to the ICR Conference to woo investors. Can its cellular health science overcome market headwinds and a volatile direct selling landscape?

Array Technologies promotes two key executives, signaling an aggressive strategy to boost global revenue and product innovation in the booming solar tracker market.

With its massive data library and AI platforms, Tempus AI prepares for a pivotal presentation. What will CEO Eric Lefkofsky reveal to investors?

Lazard Asset Management creates a new CIO role, appointing Eric Van Nostrand to unify its global investment platform amid fierce industry competition.

Newcomer Candid Therapeutics is set to unveil its T-cell engager platform at J.P. Morgan, a move that could shake up the autoimmune treatment landscape.

While US sales numbers declined in 2025, Mazda posted record CPO figures, earned top safety honors, and saw major growth in Canada and Mexico.

Cosmos Health's subsidiary will manufacture the advanced generic pain reliever PathMuscle, securing a major contract and enhancing its European footprint.

United is set to reveal its full-year 2025 earnings, putting its ambitious growth strategy and market leadership claims to the ultimate test.

Lucid crushed its 2025 production goals with a huge Q4 surge, but a widening gap between cars built and sold raises serious questions about demand.

Founder Chuck Cohn pours millions more into his ed-tech firm, a bold move that signals deep confidence despite a slumping stock and cautious analysts.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

With 35 years at the company, new CEO John Baylouny plans to accelerate R&D and expand into new markets, building on a period of strong growth.

With record Q3 earnings and strong analyst ratings, Red Violet is set to present its identity intelligence growth strategy at the prestigious Needham conference.